An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or MEtastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 28 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
- 03 May 2015 Planned End Date changed from 1 Jun 2014 to 1 Dec 2015, as reported by Clinicaltrials.gov.
- 03 May 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Dec 2015, as reported by Clinicaltrials.gov.